Dhiren R. Thakker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dhiren R. Thakker has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ruth S. Everett
Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC 27705, USA
6 shared publications Chester L. Costales
Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publicationsMatthew D. Troutman
Division of Drug Delivery and Disposition, School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
3 shared publications- Nicole R. Zane
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy at The University of North Carolina at Chapel Hill, Chapel Hill
3 shared publications Tianxiang (Kevin) Han
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, the University of North Carolina at Chapel Hill, Chapel Hill, NC
3 shared publicationsDaniel K. Benjamin
2 shared publications
Latest Publications
- Open Access
- 16 August 2019
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (10) , 759-768
Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition
Vincristine is a cytotoxic chemotherapeutic agent used as first-line therapy for pediatric acute lymphocytic leukemia. It is cleared by hepatic oxidative metabolism by CYP3A4 and CYP3A5 and via hepatic (biliary) efflux mediated by P-glycoprotein (P-gp) transporter. Bottom-up physiologically based pharmacokinetic (PBPK) models were developed to predict vincristine disposition in pediatric and adult populations. The models incorporated physicochemical properties, metabolism by CYP3A4/5, efflux by P-gp, and intracellular binding to β-tubulin. The adult and pediatric PBPK models predicted pharmacokinetics (PK) within twofold of the observed PK parameters (area under the curve, terminal half-life, volume of distribution, and clearance). Simulating a higher hypothetical (4.9-fold) pediatric expression of β-tubulin relative to adult improved predictions of vincristine PKs. To our knowledge, this is the first time that intracellular binding has been incorporated into a pediatric PBPK model. Utilizing this PBPK modeling approach, safe and effective doses of vincristine could be predicted.
- 16 August 2019
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (10) , 759-768
Open AccessPhysiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition
Vincristine is a cytotoxic chemotherapeutic agent used as first-line therapy for pediatric acute lymphocytic leukemia. It is cleared by hepatic oxidative metabolism by CYP3A4 and CYP3A5 and via hepatic (biliary) efflux mediated by P-glycoprotein (P-gp) transporter. Bottom-up physiologically based pharmacokinetic (PBPK) models were developed to predict vincristine disposition in pediatric and adult populations. The models incorporated physicochemical properties, metabolism by CYP3A4/5, efflux by P-gp, and intracellular binding to β-tubulin. The adult and pediatric PBPK models predicted pharmacokinetics (PK) within twofold of the observed PK parameters (area under the curve, terminal half-life, volume of distribution, and clearance). Simulating a higher hypothetical (4.9-fold) pediatric expression of β-tubulin relative to adult improved predictions of vincristine PKs. To our knowledge, this is the first time that intracellular binding has been incorporated into a pediatric PBPK model. Utilizing this PBPK modeling approach, safe and effective doses of vincristine could be predicted.
- Open Access
- 29 April 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (15) , 2724-2735
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours
Background and Purpose: It has been extensively reported that the leading anti‐diabetic drug, metformin, exerts significant anticancer effects. This hydrophilic, cationic drug requires cation transporters for cellular entry where it activates its intracellular target, the AMPK signalling pathway. However, clinical results on metformin therapy (used at antidiabetic doses) for breast cancer are ambiguous. It is likely that the antidiabetic dose is inadequate in patients that have breast tumours with low cation transporter expression, resulting in non‐responsiveness to the drug. We postulate that cation transporter expression and metformin dose are key determinants in its antitumour efficacy in breast cancer.Experimental Approach: Antitumour efficacy of metformin was compared between low cation transporter‐expressing MCF‐7 breast tumours and MCF‐7 tumours overexpressing organic cation transporter 3 (OCT3‐MCF7). A dose–response relationship of metformin in combination with standard‐of‐care paclitaxel (for oestrogen receptor‐positive MCF‐7 breast tumours) or carboplatin (for triple‐negative MDA‐MB‐468 breast tumours) was investigated in xenograft mice.Key Results: Metformin had greater efficacy against tumours with higher cation transporter expression, as observed in OCT3‐MCF7 versus MCF‐7 tumours and MDA‐MB‐468 versus MCF‐7 tumours. In MCF‐7 tumours, a threefold higher metformin dose was required to achieve intratumoural exposure that was comparable to exposure in MDA‐MB‐468 tumours and enhance antitumour efficacy of standard‐of‐care in MCF‐7 tumours versus MDA‐MB‐468 tumours. Antitumour efficacy correlated with intratumoural AMPK activation and metformin concentration.Conclusions and Implications: An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection.
- 29 April 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (15) , 2724-2735
Open AccessEfficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours
Background and Purpose: It has been extensively reported that the leading anti‐diabetic drug, metformin, exerts significant anticancer effects. This hydrophilic, cationic drug requires cation transporters for cellular entry where it activates its intracellular target, the AMPK signalling pathway. However, clinical results on metformin therapy (used at antidiabetic doses) for breast cancer are ambiguous. It is likely that the antidiabetic dose is inadequate in patients that have breast tumours with low cation transporter expression, resulting in non‐responsiveness to the drug. We postulate that cation transporter expression and metformin dose are key determinants in its antitumour efficacy in breast cancer.Experimental Approach: Antitumour efficacy of metformin was compared between low cation transporter‐expressing MCF‐7 breast tumours and MCF‐7 tumours overexpressing organic cation transporter 3 (OCT3‐MCF7). A dose–response relationship of metformin in combination with standard‐of‐care paclitaxel (for oestrogen receptor‐positive MCF‐7 breast tumours) or carboplatin (for triple‐negative MDA‐MB‐468 breast tumours) was investigated in xenograft mice.Key Results: Metformin had greater efficacy against tumours with higher cation transporter expression, as observed in OCT3‐MCF7 versus MCF‐7 tumours and MDA‐MB‐468 versus MCF‐7 tumours. In MCF‐7 tumours, a threefold higher metformin dose was required to achieve intratumoural exposure that was comparable to exposure in MDA‐MB‐468 tumours and enhance antitumour efficacy of standard‐of‐care in MCF‐7 tumours versus MDA‐MB‐468 tumours. Antitumour efficacy correlated with intratumoural AMPK activation and metformin concentration.Conclusions and Implications: An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection.
- Open Access
- 1 November 2017
- Published by Springer Nature in Pediatric Research
- Vol. 83 (2) , 527-535
Cytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity
Background Age-dependent differences in pharmacokinetics exist for metabolically cleared medications. Differential contributions in the cytochrome P450 3A (CYP3A), CYP2C, and flavin-containing monooxygenases (FMOs) families have an important role in the metabolic clearance of a large number of drugs administered to children. Methods Unlike previous semiquantitative characterization of age-dependent changes in the expression of genes and proteins (western blot analysis), this study quantifies both gene and absolute protein expression in the same fetal, pediatric, and adult hepatic tissue. Expression was then correlated with the corresponding functional activities in the same samples. Results CYP3A and FMO families showed a distinct switch from fetal (CYP3A7 and FMO1) to adult isoforms (CYP3A4 and FMO3) at birth, whereas CYP2C9 showed a linear maturation from birth into adulthood. In contrast, analysis of CYP2C19 revealed higher expression and catalytic efficiency in pediatric samples compared with that in fetal and adult samples. Further, CYP3A and FMO enzymes exhibited an unexpectedly higher functional activity in fetal samples not entirely explained by protein expression. Conclusion These surprising findings suggest that CYP and FMO enzymes may encounter development-related differences in their microenvironments that can influence the enzyme activity in addition to protein expression levels.
- 1 November 2017
- Published by Springer Nature in Pediatric Research
- Vol. 83 (2) , 527-535
Open AccessCytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity
Background Age-dependent differences in pharmacokinetics exist for metabolically cleared medications. Differential contributions in the cytochrome P450 3A (CYP3A), CYP2C, and flavin-containing monooxygenases (FMOs) families have an important role in the metabolic clearance of a large number of drugs administered to children. Methods Unlike previous semiquantitative characterization of age-dependent changes in the expression of genes and proteins (western blot analysis), this study quantifies both gene and absolute protein expression in the same fetal, pediatric, and adult hepatic tissue. Expression was then correlated with the corresponding functional activities in the same samples. Results CYP3A and FMO families showed a distinct switch from fetal (CYP3A7 and FMO1) to adult isoforms (CYP3A4 and FMO3) at birth, whereas CYP2C9 showed a linear maturation from birth into adulthood. In contrast, analysis of CYP2C19 revealed higher expression and catalytic efficiency in pediatric samples compared with that in fetal and adult samples. Further, CYP3A and FMO enzymes exhibited an unexpectedly higher functional activity in fetal samples not entirely explained by protein expression. Conclusion These surprising findings suggest that CYP and FMO enzymes may encounter development-related differences in their microenvironments that can influence the enzyme activity in addition to protein expression levels.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5592
Metformin for the treatment of endometrial hyperplasia.
5592 Background: We sought to evaluate the short-term response rate, toxicity and potential molecular changes following treatment with metformin for simple (SEH) and complex endometrial hyperplasia without atypia (CEH). Methods: Women with newly diagnosedsimple or complex endometrial hyperplasia without atypia by endometrial biopsy or dilation & curettage were enrolled onto a prospective multi-institutional single arm clinical trial, and treated with metformin for 3 months (850 mg daily x 4 weeks, then twice daily for 8 weeks), followed by repeat biopsy. Pathologic response and toxicity (CTCAE 4.1) were assessed. Expression of the estrogen (ER) and progesterone (PR) receptor and the metformin transporters (OCT1, OCT3, PMAT, MATE1, MATE2) were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded endometrial specimens pre- and post-treatment. Slides were scanned using the Aperio ScanScope, and digital images were analyzed using Aperio ImageScope software. We report proportions as %, along with their exact 95% confidence intervals. Pre- and post- comparisons were done using the Wilcoxon signed-rank test. Reported p-values were nominal, or unadjusted for multiple testing. Results: 18 patients enrolled, with 16 evaluable, of whom all completed treatment. 56% (9/16, 95% CI 30%, 80%) showed pathologic response (6/9 SEH, 2/5 CEH, 1/2 SEH/CEH). Common toxicities included diarrhea (67%), nausea (39%), flatulence (28%); all were grade 1 except for grade 2 diarrhea (n = 2), GERD (n = 1), and nausea (n = 1). Before metformin, the median % positive staining cells was 98.9% for ER, 89.9% for PR, 50.8% for MATE2, 98.4% for MATE1, 26.5% for PMAT, 87.5% for OCT1 and 68.6% for OCT3. Expression of MATE2 (50.8 to 60.4% positive cells; 86.1 to 120.6 H-score, p = 0.048) and OCT3 (68.6 to 91.7% positive cells; 116.8 to 136.5 H-score, p = 0.017, 0.057 respectively) increased after metformin treatment, whereas expression of MATE1, PMAT, OCT1, ER, PR did not change. Conclusions: Approximately half of the patients with endometrial hyperplasia without atypia responded to short-term metformin treatment. Preliminary exploratory comparisons seem to indicate that MATE2 and OCT3 expression (by % positive cells and H-score) increases with metformin treatment. Clinical trial information: NCT01685762.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5592
Metformin for the treatment of endometrial hyperplasia.
5592 Background: We sought to evaluate the short-term response rate, toxicity and potential molecular changes following treatment with metformin for simple (SEH) and complex endometrial hyperplasia without atypia (CEH). Methods: Women with newly diagnosedsimple or complex endometrial hyperplasia without atypia by endometrial biopsy or dilation & curettage were enrolled onto a prospective multi-institutional single arm clinical trial, and treated with metformin for 3 months (850 mg daily x 4 weeks, then twice daily for 8 weeks), followed by repeat biopsy. Pathologic response and toxicity (CTCAE 4.1) were assessed. Expression of the estrogen (ER) and progesterone (PR) receptor and the metformin transporters (OCT1, OCT3, PMAT, MATE1, MATE2) were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded endometrial specimens pre- and post-treatment. Slides were scanned using the Aperio ScanScope, and digital images were analyzed using Aperio ImageScope software. We report proportions as %, along with their exact 95% confidence intervals. Pre- and post- comparisons were done using the Wilcoxon signed-rank test. Reported p-values were nominal, or unadjusted for multiple testing. Results: 18 patients enrolled, with 16 evaluable, of whom all completed treatment. 56% (9/16, 95% CI 30%, 80%) showed pathologic response (6/9 SEH, 2/5 CEH, 1/2 SEH/CEH). Common toxicities included diarrhea (67%), nausea (39%), flatulence (28%); all were grade 1 except for grade 2 diarrhea (n = 2), GERD (n = 1), and nausea (n = 1). Before metformin, the median % positive staining cells was 98.9% for ER, 89.9% for PR, 50.8% for MATE2, 98.4% for MATE1, 26.5% for PMAT, 87.5% for OCT1 and 68.6% for OCT3. Expression of MATE2 (50.8 to 60.4% positive cells; 86.1 to 120.6 H-score, p = 0.048) and OCT3 (68.6 to 91.7% positive cells; 116.8 to 136.5 H-score, p = 0.017, 0.057 respectively) increased after metformin treatment, whereas expression of MATE1, PMAT, OCT1, ER, PR did not change. Conclusions: Approximately half of the patients with endometrial hyperplasia without atypia responded to short-term metformin treatment. Preliminary exploratory comparisons seem to indicate that MATE2 and OCT3 expression (by % positive cells and H-score) increases with metformin treatment. Clinical trial information: NCT01685762.
- 1 February 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (2) , 484-496
Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis
- 1 February 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (2) , 484-496
Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis
- Open Access
- 15 December 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (9) , 2281-2292
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells
The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers. One mechanism by which metformin is believed to exert its anticancer effect involves activation of its intracellular target, adenosine monophosphate-activated protein kinase (AMPK), which is also implicated in the antidiabetic effect of metformin. It is proposed that in cancer cells, AMPK activation leads to inhibition of the mammalian target of rapamycin (mTOR) and the downstream pS6K that regulates cell proliferation. Due to its hydrophilic and cationic nature, metformin requires cation-selective transporters to enter cells and activate AMPK. This study demonstrates that expression levels of cation-selective transporters correlate with the antiproliferative and antitumor efficacy of metformin in breast cancer. Metformin uptake and antiproliferative activity were compared between a cation-selective transporter-deficient human breast cancer cell line, BT-20, and a BT-20 cell line that was engineered to overexpress organic cation transporter 3 (OCT3), a representative of cation-selective transporters and a predominant transporter in human breast tumors. Metformin uptake was minimal in BT-20 cells, but increased by >13-fold in OCT3-BT20 cells, and its antiproliferative potency was >4-fold in OCT3-BT20 versus BT-20 cells. This increase in antiproliferative activity was associated with greater AMPK phosphorylation and decreased pS6K phosphorylation in OCT3-BT20 cells. In vitro data were corroborated by in vivo observations of significantly greater antitumor efficacy of metformin in xenograft mice bearing OCT3-overexpressing tumors versus low transporter-expressing wildtype tumors. Collectively, these findings establish a clear relationship between cation-selective transporter expression, the AMPK-mTOR-pS6K signaling cascade, and the antiproliferative activity of metformin in breast cancer.
- 15 December 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (9) , 2281-2292
Open AccessCation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells
The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers. One mechanism by which metformin is believed to exert its anticancer effect involves activation of its intracellular target, adenosine monophosphate-activated protein kinase (AMPK), which is also implicated in the antidiabetic effect of metformin. It is proposed that in cancer cells, AMPK activation leads to inhibition of the mammalian target of rapamycin (mTOR) and the downstream pS6K that regulates cell proliferation. Due to its hydrophilic and cationic nature, metformin requires cation-selective transporters to enter cells and activate AMPK. This study demonstrates that expression levels of cation-selective transporters correlate with the antiproliferative and antitumor efficacy of metformin in breast cancer. Metformin uptake and antiproliferative activity were compared between a cation-selective transporter-deficient human breast cancer cell line, BT-20, and a BT-20 cell line that was engineered to overexpress organic cation transporter 3 (OCT3), a representative of cation-selective transporters and a predominant transporter in human breast tumors. Metformin uptake was minimal in BT-20 cells, but increased by >13-fold in OCT3-BT20 cells, and its antiproliferative potency was >4-fold in OCT3-BT20 versus BT-20 cells. This increase in antiproliferative activity was associated with greater AMPK phosphorylation and decreased pS6K phosphorylation in OCT3-BT20 cells. In vitro data were corroborated by in vivo observations of significantly greater antitumor efficacy of metformin in xenograft mice bearing OCT3-overexpressing tumors versus low transporter-expressing wildtype tumors. Collectively, these findings establish a clear relationship between cation-selective transporter expression, the AMPK-mTOR-pS6K signaling cascade, and the antiproliferative activity of metformin in breast cancer.
- 4 March 2015
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 54 (5) , 569-572
Response to: “Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach”
- 4 March 2015
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 54 (5) , 569-572
Response to: “Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach”